US FDA accepts New Drug Application for avacopan for the treatment of ANCA-associated vasculitis

Avacopan is a first-in-class, orally-administered selective complement 5a receptor inhibitor. The submission includes data from the Phase II ADVOCATE trial, in which avacopan was statistically superior to prednisone in sustaining remission at 52 weeks.


Biospace Inc.